Thumbnail Image
Publication

A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma.

Hamid, O
; 
Ilaria, R
; 
Garbe, C
; 
Wolter, P
; 
Maio, M
; 
Hutson, T
; 
Arance, A
; ; 
Lee, J
; 
Hauschild, A
... show 6 more
Citations
Altmetric:
Abstract
Tasisulam sodium (hereafter referred to as tasisulam) is a novel, highly albumin-bound agent that demonstrated activity in a phase 2 melanoma study.
Authors
Hamid, O
Ilaria, R
Garbe, C
Wolter, P
Maio, M
Hutson, T
Arance, A
Lorigan, Paul C
Lee, J
Hauschild, A
Mohr, P
Hahka-Kemppinen, M
Kaiser, C
Turner, P
Conti, I
Grob, J
Affiliation
The Angeles Clinic and Research Institute, Los Angeles, California.
Description
Date
2014-07-01
Publisher
Collections
All Christie Publications
Show all metadata
Files
Thumbnail Image
cncr.28635.pdf
Adobe PDF, 211.14 KB
Keywords
Type
Article
Citation
A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma. 2014, 120 (13):2016-24 Cancer
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/325846
Embedded videos